Vyera Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from serious and neglected diseases with high unmet needs. One of Vyera’s areas of focus is toxoplasmosis.
Why Focus on Toxoplasmosis?
There has been no significant innovation in toxoplasmosis from the pharmaceutical industry in over 50 years.
Toxoplasmosis is considered a neglected parasitic infection that has been targeted as a priority for public health.
Vyera's discovery program is identifying novel drug candidates in hopes of creating a treatment that is more potent and better tolerated than existing options. Several compounds are now being tested.
Vyera aims to facilitate patient access to its treatments.
Vyera provides support to programs that assist patients who may have difficulty affording their treatment and gives discounts to organizations that provide care to underserved patients.